ISO 10993 & Regulatory
Knowledge Blog
In-depth articles and regulatory update notes on biological evaluation, EU MDR, FDA biocompatibility, CDSCO, and medical device regulatory strategy — written by a practising ISO 10993 consultant.
FDA Chemical Characterization Evidence Before 510(k)
How chemistry, TRA, and endpoint logic should work together before a 510(k) submission or Additional Information response.
Arvind Rathore
ISO 10993-17 TRA: When Chemistry Changes the BER
How ISO 10993-17 toxicological risk assessment should translate chemistry results into biological evaluation conclusions.
Arvind Rathore
EU MDR GSPR 10 Biological Evaluation Pressure Points
How GSPR 10 connects material choices, chemistry, biological evaluation, and risk management inside the technical file.
Arvind Rathore
CDSCO Biocompatibility Documentation Before Testing
What Indian device teams should clarify before ISO 10993 testing so lab data can become submission-ready BEP, BER, and TRA evidence.
Arvind Rathore
Can One ISO 10993 File Support FDA, EU MDR, and CDSCO?
How to reuse one ISO 10993 evidence package across markets while adapting BEP, BER, TRA, and endpoint narratives for each reviewer context.
Arvind Rathore
India Medical Device Parks: ISO 10993 Readiness for Startups
What India's medical-device parks mean for startups, manufacturers, biocompatibility testing, toxicology, and submission-ready BEP, BER, and TRA documentation.
Arvind Rathore
Implantable Device Biocompatibility Under ISO 10993
Why long-term implants need a different biological evaluation mindset, where FDA implant categories matter, and why sterilization, chemistry, and finished-device logic become much harder to defend.
Arvind Rathore
FDA Chemical Analysis Draft Guidance for ISO 10993-18
What FDA's still-draft chemical analysis guidance means for ISO 10993-18, chemical characterization, TRA, extractables and leachables, and 510(k) files.
Arvind Rathore
CDSCO Outsourced Sterilization Under MDR 2017: Why Manufacturers Should Recheck the File
Why CDSCO's sterilization outsourcing notice matters beyond vendor control, especially when finished-device state, residual assumptions, and lifecycle documentation need to stay aligned.
Arvind Rathore
EUDAMED Mandatory Use on 28 May 2026
Practical EU MDR checklist for the first EUDAMED mandatory-use milestone, including actor data, device registration, certificates, and document control.
Arvind Rathore
Biological Evaluation Plan (BEP) for Medical Devices
What a BEP must do under ISO 10993, what reviewers expect to see, and when BEP drafting, BEP review, or broader file triage is the right next step.
Arvind Rathore
Common BEP Mistakes That Trigger Reviewer Questions
The planning mistakes that make a Biological Evaluation Plan look generic, reverse-engineered, or weak before the rest of the file is even reviewed.
Arvind Rathore
Biological Evaluation Report (BER) for Medical Devices
What a BER must do under ISO 10993, where reports usually fail, what reviewers expect, and when BER drafting or review support is the right next step.
Arvind Rathore
ISO 10993-1:2025 — The Lifecycle Approach Changes Everything
The 2025 revision of ISO 10993-1 is not just a terminology update. It fundamentally reframes how biological safety must be evaluated across the entire device lifecycle — and many existing BEPs have gaps.
Arvind Rathore
CDSCO vs FDA vs EU MDR: How Biocompatibility Documentation Expectations Differ
A practical comparison of what stays reusable across India, FDA, and EU MDR submissions, what must be reframed, and where teams get into trouble by copying the same file across markets.
Arvind Rathore
BEP vs BER Under ISO 10993
Biological Evaluation Plan vs Biological Evaluation Report under ISO 10993, including what each document does, when you need them, and where teams confuse them.
Arvind Rathore
Biocompatibility Evaluation for Medical Devices
What biocompatibility evaluation really means under ISO 10993, where BEP and BER fit, when TRA matters, and why testing alone is not the whole biological-safety argument.
Arvind Rathore
Central Drugs Standard Control Organization (CDSCO) Guide
How the Central Drugs Standard Control Organization (CDSCO) usually expects biocompatibility to be framed for India medical-device files under MDR 2017, including where ISO 10993 fits.
Arvind Rathore
FDA Biocompatibility Expectations for 510(k) Files in 2026
Practical FDA 510(k) expectations in 2026, including the file weaknesses that still trigger avoidable Additional Information requests.
Arvind Rathore
When ISO 10993-1:2025 Actually Changes the File — and When It Doesn’t
A practical update on where the 2025 revision truly changes BEP and BER work, and when selective remediation is smarter than a full rewrite.
Arvind Rathore
Chemical Characterization Under ISO 10993: What Reviewers Expect
Chemical characterization is no longer supporting data that can sit in the appendix. For many devices, it is the backbone of the chemistry-driven biological safety argument.
Arvind Rathore
5 Reasons FDA Rejects 510(k) Biocompatibility Sections
FDA additional information (AI) requests for biocompatibility are among the most common 510(k) delays. These are the five patterns seen most frequently — and how to avoid every one of them.
Arvind Rathore
FDA AI Responses for Biocompatibility: How to Fix the File
What FDA Additional Information requests on biocompatibility usually mean, how to respond without creating new gaps, and why the best fix often starts in the underlying file.
Arvind Rathore
Can Biological Tests Be Waived? Yes — If Done Correctly
Test waivers are not shortcuts. They are a scientifically rigorous alternative to in vitro or in vivo testing — and ISO 10993-1:2025 actively encourages their use when existing data is sufficient.
Arvind Rathore
EU MDR Annex I §10 — What Notified Bodies Actually Check
Section 10 of Annex I (GSPR) covers chemical, physical, and biological properties. It is one of the most scrutinised sections in EU MDR technical files. Here is what notified bodies look for.
Arvind Rathore
Toxicological Risk Assessment (TRA): ISO 10993-17 Guide
How TRA supports ISO 10993 medical-device files, chemistry-driven endpoint waivers, ISO 10993-17/18 logic, and when TRA service support is needed.
Arvind Rathore
ISO 10993-5 Cytotoxicity Testing: Results, Waivers, and BER Use
What cytotoxicity testing measures, how to interpret passing or borderline results, when waiver logic may fit, and why the result is only one part of the BEP or BER.
Arvind Rathore
ISO 14971 + ISO 10993 Must Work Together
Biological safety is not a standalone compliance checkbox. It is a risk management activity. ISO 10993-1:2025 explicitly requires integration with the ISO 14971 risk management framework.
Arvind Rathore
Material Change? Your Biological Evaluation Needs Re-Assessment
A change to any material in contact with the patient — supplier change, formulation update, coating modification — triggers a structured biological re-evaluation. Here is how to handle it.
Arvind Rathore
ISO 13485 and Biological Evaluation: Where QMS Meets Safety Science
ISO 13485 requires that biological evaluation be managed as a controlled design activity. Understanding how QMS requirements intersect with ISO 10993 documentation prevents the most common audit findings.
Arvind Rathore
Contact Classification: The Foundation of Every Biological Evaluation
Before you can select biological evaluation endpoints, you must correctly classify your device by contact nature and duration. Getting this wrong means your entire evaluation is built on an incorrect foundation.
Arvind Rathore
Scientific Writing for Medical Device Regulatory Submissions
Regulatory documents are scientific documents. They are reviewed by scientists and clinicians who expect precision, clarity, and evidence. The writing standard expected in a BER or CER is closer to a journal article than a technical report.
Arvind Rathore
Get Public Regulatory Updates
LinkedIn is where I share public commentary on ISO 10993, EU MDR, and FDA biocompatibility topics between client projects and longer website articles.